Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04350138 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection
A Phase 2 study of Gonococcal Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 2
- Development phase
- 2,606
- Enrollment target
- 13
- Study locations
NCT04350138: Active Phase 2 study of Gonococcal Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT04350138 is a Phase 2 study of Gonococcal Infection that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,606 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1859% higher). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04350138, a Phase 2 study of Gonococcal Infection, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 2,606 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participants are expected to be enrolled to achieve at least 202 primary endpoints in the Per Protocol Population. Data will be collected in an observer-blind manner. Study product recipients and study staff responsible for the evaluation of any study endpoint will be unaware of whether Bexsero or placebo were administered. The duration of the study for participants who are enrolled and randomized will be approximately 16 months. Study participation is expected to be completed in approximately 36 months. The primary objective of the study is to demonstrate efficacy of Bexsero in prevention of urogenital and/or anorectal gonococcal infection.
Primary Outcome
Confirmed by Nucleic Acid Amplification Test (NAAT).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Meningococcal Group B Vaccine
Study Locations (13)
California
- UCLA Clinical AIDS Research and Education (CARE) Center - Los Angeles
- SFDPH Bridge HIV Center - San Francisco
Georgia
- Emory University School of Medicine - The Ponce de Leon Center - Atlanta
- Emory University Hospital Midtown - Emory Clinic Infectious Diseases - Atlanta
Other
- The Thai Red Cross AIDS Research Centre - Bangkok
- Armed Forces Research Institute of Medical Sciences - Royal Thai Army Clinical Research Center - Bangkok
Alabama
- University of Alabama at Birmingham School of Medicine - Infectious Disease - Birmingham
Illinois
- University of Illinois at Chicago College of Medicine - Division of Infectious Diseases - Chicago
Louisiana
- LSU - CrescentCare Sexual Health Center - New Orleans
Maryland
- Walter Reed National Military Medical Center - Bethesda
New York
- Harlem Prevention Center, Columbia University, Mailman School of Public Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,606 participants |
| Start Date | 2020-12-29 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
What the registry record for NCT04350138 still lists
NCT04350138 is an interventional study that assigns participants to a tested intervention. Its 2,606 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1859% higher).
The record links to 1 condition, with Gonococcal Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04350138 lists 13 locations in 10 states (California, Georgia, Other).
Frequently Asked Questions
What is clinical trial NCT04350138 about?
NCT04350138 is a clinical study titled "Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection". This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participant...
What is the current status of trial NCT04350138?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 2,606 participants. The study started on 2020-12-29. Estimated completion is 2026-10-01.
What conditions does trial NCT04350138 study?
This clinical trial studies the following conditions: Gonococcal Infection.
What interventions are being tested in trial NCT04350138?
The interventions under investigation include: Placebo (OTHER), Meningococcal Group B Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04350138?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04350138 being conducted?
This trial has 13 study locations across Alabama, California, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gonococcal Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04350138's enrollment target sits among peer trials
2,606 7th of 2000 higher than 1,994 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI